# US 2022/0276139 A1 · Compositions and methods for clearing tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276139 A1
- Document ID: US20220276139A1
- Status: Published application
- Kind: A1
- Application number: 17/625,665
- Filed: 2019-07-08
- Published: 2022-09-01
- Earliest claimed: 2019-07-08
- Assignees: The University of Hong Kong
- Applicants: The University of Hong Kong
- Inventors: Hei Ming Lai; Tak Mao Daniel Chan; Sou Ying Susan Yung
- Web page: https://patentgrep.com/patent/US20220276139A1

## CPC

- G01N 1/34: Purifying; Cleaning {(processes or apparatus for extracting or separating nucleic acids from biological samples C12N15/1003)}
- C11D 7/08: Acids
- C11D 7/32: containing nitrogen
- C11D 7/329: {Carbohydrate or derivatives thereof}
- G01N 1/30: Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C11D: DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL

## Abstract

Investigation of fine tissue structures, such as those in non-neural, non-osseous tissues or organs, is best performed in intact tissue. Described herein are compositions and methods for clearing tissues for subsequent three-dimensional analysis. The compositions referred to herein as tissue clearing compositions are composed of four core components: (1) a homogenizing agent such as N-methylglucamine, urea, thiourea, guanidine, guanidinium chloride, lithium perchlorate, ethylenediamine, and derivatives thereof; (2) a water-soluble adjusting agent such as iohexol, sodium thiosulfate, polyethylene glycol, and derivatives thereof; (3) a lipid-soluble adjusting agent such as 2,2′-thiodiethanol, propylene glycol, and derivatives thereof; and (4) a borate compound such as boric acid, tetraboric acid, disodium tetraborate, and derivatives thereof. The disclosed tissue clearing compositions are particularly suitable for use with non-neural, non-osseous tissues or organs. The tissues or organs can be fresh, archived, or retrieved from paraffin wax-embedded tissues.

## Claims

### Claim 1

A tissue clearing composition comprising a homogenizing agent, a water-soluble adjusting agent, a lipid-soluble adjusting agent, and a borate compound.

### Claim 2 (depends on 1)

The tissue clearing composition of claim 1, wherein the borate compound is a hydrogen or metal borate in an anhydrous or hydrous form.

### Claim 3 (depends on 1)

The tissue clearing composition of claim 1, wherein the borate compound is a hydrogen borate selected from the group consisting of boric acid (H3BO3), metaboric acid (H3B3O6), and tetraboric acid (H2B4O7).

### Claim 4 (depends on 1)

The tissue clearing composition of claim 1, wherein the borate compound is a metal borate having a boron-containing oxyanion selected from the group consisting of metaborates (BO2−), diborate (B2O54−), triborate (B3O75−), tetraborate (B4O72−, B4O5(OH)42−, B4O96−, or combinations thereof), and hydroxyborate (B(OH)4−).

### Claim 5 (depends on 1)

The tissue clearing composition of claim 1, wherein the borate compound is selected from the group consisting of boric acid, tetraboric acid, disodium tetraborate, and derivatives thereof.

### Claim 6 (depends on 1)

The tissue clearing composition of claim 1, wherein the molar ratio of the homogenizing agent to the borate compound is between about 0.5 and about 2, preferably about 1.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The tissue clearing composition of claim 1, wherein the homogenizing agent is a denaturant of proteins, nucleic acids, or a combination thereof.

### Claim at position 9

9-12. (canceled)

### Claim 13 (depends on 1)

The tissue clearing composition of claim 1, wherein the water-soluble adjusting agent, the lipid-soluble adjusting agent, or both have a refractive index higher than that of water at 25° C., preferably between about 1.40 and about 1.50 at 25° C.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The tissue clearing composition of claim 1, wherein the refractive index of the water-soluble adjusting agent is at or within 10% of the refractive index of the lipid-soluble adjusting agent at 25° C.

### Claim at position 13

16-17. (canceled)

### Claim 18 (depends on 1)

The tissue clearing composition of claim 1, wherein the lipid-soluble adjusting agent is miscible with water.

### Claim at position 15

19-20. (canceled)

### Claim 21 (depends on 1)

The tissue clearing composition of claim 1, wherein
(a) the homogenizing agent is selected from the group consisting of N-methylglucamine, urea, thiourea, guanidine, guanidinium chloride, lithium perchlorate, ethylenediamine, and derivatives thereof;
(b) the water-soluble adjusting agent is selected from the group consisting of iohexol, sodium thiosulfate, polyethylene glycol, and derivatives thereof;
(c) the lipid-soluble adjusting agent is selected from the group consisting of 2,2′-thiodiethanol, propylene glycol, and derivatives thereof; and
(d) the borate compound is selected from the group consisting of boric acid, tetraboric acid, disodium tetraborate, and derivatives thereof.

### Claim 22 (depends on 21)

The tissue clearing composition of claim 21, wherein the homogenizing agent is N-methylglucamine, the water-soluble adjusting agent is iohexol, the lipid-soluble adjusting agent is 2,2′-thiodiethanol, and the borate compound is boric acid.

### Claim 23 (depends on 22)

The tissue clearing composition of claim 22, wherein the concentration of each of N-methylglucamine, iohexol, and 2,2′-thiodiethanol ranges from about 10 to about 50 w/v %, and the molar ratio of N-methylglucamine to boric acid is between about 0.5 and about 2.

### Claim 24

(canceled)

### Claim 25 (depends on 21)

The tissue clearing composition of claim 21, wherein the homogenizing agent is N-methylglucamine, the water-soluble adjusting agent is iohexol, the lipid-soluble adjusting agent is propylene glycol, and the borate compound is boric acid.

### Claim 26 (depends on 25)

The tissue clearing composition of claim 25, wherein the concentration of each of N-methylglucamine and iohexol ranges from about 10% to about 50%, the concentration of propylene glycol ranges from about 10 to about 60 w/v %, and the molar ratio of N-methylglucamine to boric acid is between about 0.5 and about 2.

### Claim 27

(canceled)

### Claim 28 (depends on 21)

The tissue clearing composition of claim 21, wherein the homogenizing agent is urea, the water-soluble adjusting agent is iohexol, the lipid-soluble adjusting agent is 2,2′-thiodiethanol, and the borate compound is boric acid.

### Claim 29 (depends on 28)

The tissue clearing composition of claim 28, wherein the concentration of urea ranges from about 5 to about 50 w/v %, the concentration of each of iohexol and 2,2′-thiodiethanol ranges from about 10 to about 50 w/v %, and the molar ratio of urea to boric acid is between about 0.5 and about 2.

### Claim 30

(canceled)

### Claim 31 (depends on 1)

The tissue clearing composition of claim 1, further comprising one or more excipients selected from liquid vehicles, dispersion or suspension aids, surfactants, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, and combinations thereof.

### Claim at position 27

32-34. (canceled)

### Claim 35 (depends on 1)

The tissue clearing composition of claim 1, wherein the tissue clearing composition has a refractive index between about 1.4 and about 1.5 at 25° C.

### Claim 36 (depends on 1)

The tissue clearing composition of claim 1, wherein the tissue clearing composition has a pH in the range from about 5 to about 9, from about 5.5 to about 8.5, from about 6 to about 8, or from about 7 to about 10.

### Claim 37 (depends on 1)

The tissue clearing composition of claim 1, wherein the tissue clearing composition shows improved tissue clearing capacity for non-neural, non-osseous tissues or organs relative to corresponding compositions without the borate compound, relative to corresponding compositions with the borate compound replaced by an organic or inorganic acid, or relative to both.

### Claim 38 (depends on 1)

A method of clearing tissues comprising incubating a tissue sample in the tissue clearing composition of claim 1.

### Claim 39 (depends on 38)

The method of claim 38, wherein the homogenizing agent is N-methylglucamine, the water-soluble adjusting agent is iohexol, the lipid-soluble adjusting agent is 2,2′-thiodiethanol, and the borate compound is boric acid.

### Claim 40 (depends on 39)

The method of claim 39, wherein the concentration of each of N-methylglucamine, iohexol, and 2,2′-thiodiethanol ranges from about 10 to about 50 w/v %, and the molar ratio of N-methylglucamine to boric acid is between about 0.5 and about 2.

### Claim 41 (depends on 40)

The method of claim 40, wherein the concentration of N-methylglucamine is about 20 w/v %, the concentration of iohexol is about 32 w/v %, the concentration of thiodiethanol is about 25 w/v %, and the molar ratio of N-methylglucamine to boric acid is about 1.

### Claim 42 (depends on 38)

The method of claim 38, wherein the tissue sample is incubated for a period of time ranging from about 3 to about 24 hours at a temperature ranging from about 37 to about 55° C.

### Claim 43 (depends on 38)

The method of claim 38, wherein the tissue sample is a mammalian tissue sample, preferably a human tissue sample.

### Claim 44

(canceled)

### Claim 45 (depends on 38)

The method of claim 38, wherein the tissue sample is from a non-neural, non-osseous tissue or organ.

### Claim 46

(canceled)

### Claim 47 (depends on 38)

The method of claim 38, wherein the tissue sample is a renal tissue sample or a tumor tissue.

### Claim at position 41

48-50. (canceled)

### Claim 51 (depends on 38)

The method of claim 38, wherein the tissue sample is fresh, archived, or retrieved from a paraffin wax-embedded tissue.

### Claim 52 (depends on 38)

The method of claim 38, further comprising, prior to incubating the tissue sample:
(a) selecting a homogenizing agent, a water-soluble adjusting agent, a lipid-soluble adjusting agent, and a borate compound; and
(b) mixing the homogenizing agent, water-soluble adjusting agent, lipid-soluble adjusting agent, and borate compound to form the tissue clearing composition.

### Claim 53 (depends on 38)

The method of claim 38, further comprising, before or after incubating the tissue sample, one or more of the following steps, in any order:
(i) staining the tissue sample using one or more fluorescent dyes;
(ii) imaging one or more fluorescent proteins expressed in the tissue sample;
(iii) performing immunohistochemistry, fluorescent histochemistry, or both on the tissue sample; and
(iv) characterizing the tissue sample using transmission electron microscopy.
